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851-3 Prognostic Implications of Ischemlc MItral 
Regurgitation in Patients With Myocardial Infarction 
Ramdas G. Pal, Padmini Varedarajan, VA Medical Center, Loma Linda, California. Loma 
Linda Universi~ Loma Linda, Cafifomia. 
Background: Mitral regurgitation (MR) is frequent in patients with myocardial infarction 
(MI). Prognostic importance of angiographicaUy detected MR is well documented. How- 
ever, angiography is performed in higher risk patients. Echocardiography on the other 
hand is more commonly performed in lower risk patients. But the prognostic implications 
of echocardiographically detected MR in the modern era is uncertain. 
Methods and results: The echocardiographic database search in our laboratory from 
1990 to 99 yielded 2623 patients who had evidence of MI (ie pathological Q waves) in 
concurrently obtained electrocardiograms - anterior in 668 and inferior in 2178 (both in 
460). MR by Framingham criteria was present in 1566 (60%) patients - trivial in 455 
(17%), mild in 796 (31%), moderate in 227 (9%) and severe in 88 (3%). Other patient 
characteristics: age 69(11) years, LV ejection fraction 46(16)%, 736 deaths over 3 years. 
Patients with trivial MR had a survival curve similar to those with no MR (5 year survival 
of 73%). However, surviva) was significantly lower in those with mild, moderate and 
severe degrees of MR (5 year survival 60, 49 and 30% respectively, p<0.0001 ). Deleteri- 
ous effect of MR was present in both anterior and inferior MI. There was a strong associ- 
ation between increasing degrees of MR and older age (p<0.0001), and lower EF 
(p<0.0001). Proportional hazards model identified MR (p=0.009) to be an independent 
correlate of survival after correcting for age and EF (both p<0.0001). 
Conclusions: 1) MR is frequent in MI and adversely affects prognosis. 2) It is related to 
age and LV dysfunction rather than MI location. 3) Its impact on mortality is independent 
of age and degree of LV dysfunction. 4) Even mild MR is a high risk indicator. 5) Optimal 
management of MR in MI warrants further investigations. 
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851-4 Baseline Risk Predicts Therapeutic Efficacy Differences 
Between Coronary Bypass and Coronary Angioplesty 
Charaniit S. Rihal. Manuel S. Lombardero, Gabriel Silverman, Katherine M. Datre, 
Hartze[I V. Schaff, and Bernard J. Gersh for the BARI Investigators, Mayo Clinic and 
Foundation, Rochester, Minnesota, University of Pittsburgh, Pittsburgh, Pennsylvania. 
Background: The Bypass Angioplasty Revascularization Investigation (BARI) found that 
diabetes mellitus before ravasculadzation predicts differences between bypass surgery 
and angioplasty. The effects of more complex combinations of baseline factors have not 
been examined. We hypothesized that benefits of CABG over PTCA, if any, were propor- 
tional to baseline risk. 
Methods: Baseline risk for the BARI population (trial + registry) was estimated with a mul- 
tivariate risk score developed by the CABG Surgery Trialists Collaboration using a model 
to predict 10-year mortality. (Lancet 1994;344:563-70) that included both clinicaJ (age, 
angina, history of myocardial infarction, diabetes, hypertension, and ejection fraction) 
and angiographic (right coronary or proximal LAD lesion) variables. Pts were divided into 
quintiles of risk and long-term all-cause mortality differences assessed with the log-rank 
statistic. 
Results: 3610 pts (mean age 61.5 years, 74% male) were included in the analysis. 1517 
underwent CABG and 2093 PTCA, Vital status was available for 97% and mean follow 
up was 7.7 years. 
Conclusions: Baseline risk, as determined by an independently derived multivariable 
equation, accurately stratified pts. Observed long-term mortality at the highest levels of 
risk was lower after CABG compared to PTCA but equivalent at lower levels of risk. 
CABG is to be preferred over PTCA among high-risk pts, but either procedure is suitable 
at low and moderate levels of risk. 
Risk Quintile 1 2 3 4 5 
5-Year Mortality PTCA (%) 6.5 4.1 9.0 13.8 21.5 
5-Year Mortality CABG (%) 4.2 6.8 8.3 11.5 16.4 
P, Log-Rank Test NS NS NS 0.088 0.0204 
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851-5 Report  o f  Erecti le Dysfunction After Therapy With Beta- 
Blockers Is Related to Patient Knowledge of Side 
Effects and is Reversed by Both Sildenafil Citrate and 
Placebo 
Giuseooe M. Rosano, Giuseppe Mercuro, Filippo Leonardo, Paolo Pagnotta, Roberto 
Pathzi, Massimo Fini, San Raffaele Hospital, Roma, Italy, University of Cagliad, Cagliad, 
Italy. 
Patients with cardiovascular diseases (CVD) frequently complain of erectile dysfunction 
especially when treated with beta-blockers. In order to assess whether the effect of beta- 
blockers on erectile dysfunction is, in part related to patient knowledge of the drug side 
effects 96 male patients with CVD entered a double-blinded parallel study. Thirty-two 
patients atenolol 50 mg (A) without knowledge of the drug they were administered, 32 
received A knowing that the drug was a beta-blocker and 32 received A knowing that the 
drug they were taking was a beta-blocker and that it could have given erectile dysfunc- 
tion. 
After 3 months patients were administered a quality of life questionnaire containing ques- 
tions about erection. 
The incidence of erectile dysfunction was 3% in the group not knowing which drug they 
were taking, 16% in the group knowing that they were receiving a beta-blocker and 30% 
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in the group also knowing the side effects of the drug (p<0.01). Patients reporting erectile 
dysfunction entered a double blind placebo controlled study on the effect of Sildenafil Cit- 
rate on the reversal of beta-blocker-induced erectile dysfunction. Sildenafil citrate and 
placebo were equally effective in reversing erectile dysfunction in all but one patient in 
whom only withdrawal of beta-blockade was effective in reversing erectiledysfunction.. 
In conclusion in male patients with CVD the report of erectile dysfunction after therapy 
with beta-blockers is largely related to patient knowledge of the drug side effects as it is 
almost always completely reversed by a placebo drug. 
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851-6 Gender Differences in Extent and Severity of Coronary 
Disease in the ACC National Cardiovascular Disease 
Registry 
Laslee J. Shaw, Raymond J. Gibbons, Ben McCallister, Kristi R. Mitchell, Kathleen 
Hewitt, Lloyd W. Klein, William S. Weintreub, Ralph G. Brindis, Richard E. Shaw, Atlanta 
Cardiovascular Research Institute, Atlanta, Georgia, Mayo Clinic, Rochester, Minnesota. 
Background: The evaluation of women (W) with suspected coronary disease (CAD) 
remains a difficult diagnostic dilemma due to varying presentation and test accuracy. 
Methods: A total of 43,629 elective diagnostic cardiac catheterizations performed for sta- 
ble symptoms or provocative ischamia in 184 hospitals in 1999-2000. Multivadable logis- 
tic regression models were used to estimate 1) significant (>=70% stenosis) and 2) 
severe CAD (3 vessel or left main). 
Results: W comprise 45% of patients and were older with more hypertension, diabetes, 
vascular disease, atypical angina, and heart failure symptoms. Significant and severe 
CAD rates were 30% and 7% in W and 48% and 15% in men (p<0.0001, see Table). In 
multivariable models, female gender was an independent predictor of significant (odds 
ratio[OR]=2.6, 95% C1=2.5-2.6, p<0.000t) and severe CAD (OR=2.5, 98% C1=2.3-2.7, 
p<0.0001 ). For W, significant CAD predictors were age, typical angina, vascular disease, 
hypertension, hypercholesterolemia, positive stress test, smoking, and diabetes 
(Z2=2769, p<0.OO01, r2=.16). Severe CAD predictors were age, typical angina, vascular 
disease, hypercholesterolemia, diabetes, and smoking (X2=768, p<O.O001, r2=.05). 
Conclusions: Due to lower rates of obstructive CAD in women, predictive algorithms and 
clinical guidelines should consider development of separate male and female diagnostic 
strategies for optimal disease detection including newer, more aggressive screening 
approaches for women. 
0 >0<50% 50-69% 1 Vessel 2 Vessel 3 Vessel or Left 
Stenosis Stenosis Stenosis CAD CAD Main CAD 
Women 48% 14% 8% 16% 7% 7% 
(n=19761) 
Men 32% 12% 8% 21% 12% 15% 
(n=23868) 
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852-1 Persistent Activation of the NF-K B Signaling Pathway 
in Pat ients  With Unstable Angina and Elevated Levels of 
C-Reactive Protein 
Giovanna Liuzzo. Matteo Santamaria, Francesca Ginnetti, Annalisa Porto, Dominick J. 
Angiolillo, Vittoria Rizzello, Luigi M. Biasucci, Cardiology, Catholic Universi~ Rome, Italy, 
Background: Elevated levels of C-reactive protein (CRP) are associated with an 
increased risk of persistent instability, death and myocardial infarction in patients with 
acute coronary syndromes. However, it is still unclear whether CRP is simply a marker of 
disease activity or a pathogenatic component of instability. Recent reports have sug- 
gested that CRP may amplify the response to other pro-inflammatory stimuli and that a 
specific activation of the nuclear transcription factor NF-K B may be involved in this pro- 
cess. The aim of the present study was to explore the contribution of the NF-K B signal- 
ing pathway to the enhanced inflammatory response observed in patients with unstable 
angina (UA). 
Methods: We studied 12 patients with history of UA and persistently elevated levels of 
CRP (>3mg/L), followed for 12 months and free of symptoms for at least 3 months, and 
12 patients with chronic stable angina (SA) and normal CRP. Freshly isolated peripheral 
blood monocytes (MO) were analyzed for spontaneous NF-K B activation by electro- 
phoretic mobility shift assay, and for IL-6 production after in vitro stimulation with low 
dose of lipopolysaccharide (LPS) (lng/mL, for 4 hours). 
Results: Evidence for NF-~< B signaling in vivo was provided by demonstrating the 
nuclear presence of NF-~ B complexes in MO freshly isolated from 9/12 (75%) UA ver- 
sus 2/12 (17%) SA patients (P=0.014). As expected, LPS-stimuiated IL-6 production 
(median, range) was significantly higher in UA (3.3 ng/ml, 2.5-7.9) than in SA (2.1 ng/ml, 
0.2-4.5) (P<0.01). In the overall population, IL-6 production in response to LPS was lin- 
eady correlated with baseline levels of CRP (r=0.49, P<0.01) and with the NF-I< B activa- 
tion status (r=0.39, P= 0.04). 
Conclusions: Circulating MO from UA patients with persistently elevated levels of CRP 
exhibit a specific activation of the nuclear transcription factor NF-E B, 3 months after the 
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